Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Repositioning of the global epicentre of non-optimal cholesterol

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A roadmap for the Human Developmental Cell Atlas

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Germline Elongator mutations in Sonic Hedgehog medulloblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Pan-cancer analysis of whole genomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Atrial fibrillation and chronic kidney disease

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  3. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • NCD Risk Factor Collaboration (NCD-RisC)
Vis graf over relationer

High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular risk-changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.

OriginalsprogEngelsk
TidsskriftNature
Vol/bind582
Udgave nummer7810
Sider (fra-til)73-77
Antal sider5
ISSN0028-0836
DOI
StatusUdgivet - 4 jun. 2020

Bibliografisk note

Funding Information:
Acknowledgements This study was funded by a Wellcome Trust (Biomedical Resource & Multi-User Equipment grant 01506/Z/13/Z) and the British Heart Foundation (Centre of Research Excellence grant RE/18/4/34215). C.T. was supported by a Wellcome Trust Research Training Fellowship (203616/Z/16/Z). The authors alone are responsible for the views expressed in this Article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated.

Funding Information:
Competing interests M.E. reports a charitable grant from the AstraZeneca Young Health Programme, and personal fees from Prudential, Scor and Third Bridge, outside the submitted work. The other authors declare no competing interests.

ID: 60005801